The immunosuppressive agent mizoribine monophosphate forms a transition state analogue complex with inosine monophosphate dehydrogenase

被引:54
作者
Gan, L
Seyedsayamdost, MR
Shuto, S
Matsuda, A
Petsko, GA
Hedstrom, L [1 ]
机构
[1] Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA
[2] Brandeis Univ, Dept Chem, Waltham, MA 02454 USA
[3] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA
[4] Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan
关键词
D O I
10.1021/bi0271401
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mizoribine monophosphate (MZP) is the active metabolite of the immunosuppressive agent mizoribine and a potent inhibitor of IMP dehydrogenase (IMPDH). This enzyme catalyzes the oxidation of IMP to XMP with the concomitant reduction of NAD via a covalent intermediate at Cys319 (E-XMP*). Surprisingly, mutational analysis indicates that MZP is a transition state analogue although its structure does not resemble that of the expected transition state. Here we report the X-ray crystal structure of the E(.)MZP complex at 2.0 Angstrom resolution that reveals a transition state-like structure and solves the mechanistic puzzle of the IMPDH reaction. The protein assumes a new conformation where a flap folds into the NAD site and MZP, Cys319, and a water molecule are arranged in a geometry resembling the transition state. The water appears to be activated by interactions with a conserved Arg418-Tyr419 dyad. Mutagenesis experiments confirm that this new closed conformation is required for the hydrolysis of E-XMP*, but not for the reduction of NAD. The closed conformation provides a structural explanation for the differences in drug selectivity and catalytic efficiency of IMPDH isozymes.
引用
收藏
页码:857 / 863
页数:7
相关论文
共 39 条
[1]   IMMUNOSUPPRESSIVE AND OTHER EFFECTS OF MYCOPHENOLIC-ACID AND AN ESTER PRODRUG, MYCOPHENOLATE MOFETIL [J].
ALLISON, AC ;
EUGUI, EM .
IMMUNOLOGICAL REVIEWS, 1993, 136 :5-28
[2]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[3]   Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design [J].
Colby, TD ;
Vanderveen, K ;
Strickler, MD ;
Markham, GD ;
Goldstein, BM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3531-3536
[4]   Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid [J].
Digits, JA ;
Hedstrom, L .
BIOCHEMISTRY, 1999, 38 (46) :15388-15397
[5]   Drug selectivity is determined by coupling across the NAD+ site of IMP dehydrogenase [J].
Digits, JA ;
Hedstrom, L .
BIOCHEMISTRY, 2000, 39 (07) :1771-1777
[6]   Kinetic mechanism of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase [J].
Digits, JA ;
Hedstrom, L .
BIOCHEMISTRY, 1999, 38 (08) :2295-2306
[7]  
Franchetti P, 1999, CURR MED CHEM, V6, P599
[8]   A mutational analysis of the active site of human type II inosine 5′-monophosphate dehydrogenase [J].
Futer, O ;
Sintchak, MD ;
Caron, PR ;
Nimmesgern, E ;
DeCenzo, MT ;
Livingston, DJ ;
Raybuck, SA .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2002, 1594 (01) :27-39
[9]   Crystal structure of a ternary complex of Tritrichomonas foetus inosine 5′-monophosphate dehydrogenase:: NAD+ orients the active site loop for catalysis [J].
Gan, L ;
Petsko, GA ;
Hedstrom, L .
BIOCHEMISTRY, 2002, 41 (44) :13309-13317
[10]  
Goldstein BM, 1999, CURR MED CHEM, V6, P519